MARKET

GOVXW

GOVXW

GEOVAX LABS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.260
+0.060
+5.00%
Closed 16:00 05/18 EDT
OPEN
1.120
PREV CLOSE
1.200
HIGH
1.350
LOW
1.120
VOLUME
2.30K
TURNOVER
--
52 WEEK HIGH
4.480
52 WEEK LOW
0.4917
MARKET CAP
--
P/E (TTM)
-0.6207
1D
5D
1M
3M
1Y
5Y
BRIEF-Geovax Reports 2021 First Quarter Financial Results And Provides Corporate Update
reuters.com · 05/06 20:03
GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021
EQNX::TICKER_START (NASDAQ:GOVX),(NASDAQ:GOVXW), EQNX::TICKER_END
GlobeNewswire · 05/06 15:30
BRIEF-Geovax Labs Receives Notice Of Allowance For Hepatitis B Vaccine Patent
reuters.com · 04/01 13:18
GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference
Virtual Conference to be Held March 9-10, 2021 ATLANTA, GA, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, ...
GlobeNewswire · 03/03 14:00
BRIEF-Geovax Announces Pricing Of $9 Million Bought Deal Offering
reuters.com · 02/09 04:46
BRIEF-Geovax Labs Inc Files For Mixed Shelf Of Upto $100 Million - SEC Filing
reuters.com · 01/26 22:05
GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq
ATLANTA, GA, Sept. 29, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the closing of its underwritten
GlobeNewswire · 09/29/2020 18:00
Forecast
Actual (M USD)
Estimate (M USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GOVXW. Analyze the recent business situations of GEOVAX LABS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Dodd
Chief Financial Officer/Secretary
Mark Reynolds
Chief Scientific Officer
Mark Newman
Chief Scientific Officer
Harriet Robinson
Director
Robert McNally
Independent Director
Randal Chase
Independent Director
Dean Kollintzas
Independent Director
John Spencer
No Data
About GOVXW
GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company's platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. The Company's development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg and Lassa Fever), as well as for use in cancer immunotherapy. The Company's clinically advanced vaccine development program is a (deoxyribonucleic acid (DNA)/MVA) vaccine regimen designed to protect against the clade B subtype of the HIV virus. The Company is developing a Tetravalent Vaccine (TV) utilizing its MVA-VLP platform to address the unmet need for a product that can respond to future filovirus epidemics.

Webull offers kinds of Geovax Labs Inc stock information, including NASDAQ:GOVXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOVXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOVXW stock methods without spending real money on the virtual paper trading platform.